-+ 0.00%
-+ 0.00%
-+ 0.00%

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Benzinga·04/01/2025 12:05:42
Listen to the news

Gainers

  • bioAffinity Technologies (NASDAQ:BIAF) shares rose 187.3% to $0.75 during Tuesday's pre-market session. The company's market cap stands at $11.6 million. The company's, Q4 earnings came out yesterday.
  • Reshape Lifesciences (NASDAQ:RSLS) shares moved upwards by 137.3% to $0.86. The market value of their outstanding shares is at $2.8 million.
  • Nutex Health (NASDAQ:NUTX) shares moved upwards by 42.46% to $67.0. The company's market cap stands at $364.2 million. As per the press release, Q4 earnings came out yesterday.
  • Gain Therapeutics (NASDAQ:GANX) stock increased by 27.1% to $2.43. The market value of their outstanding shares is at $64.3 million. As per the press release, Q4 earnings came out 3 days ago.
  • Sharps Technology (NASDAQ:STSS) shares moved upwards by 25.08% to $0.04.
  • Impact BioMedical (AMEX:IBO) shares moved upwards by 24.13% to $1.08. The market value of their outstanding shares is at $12.4 million.

Losers

  • Performant Healthcare (NASDAQ:PHLT) stock declined by 52.7% to $1.4 during Tuesday's pre-market session. The company's market cap stands at $109.6 million.
  • InnovAge Holding (NASDAQ:INNV) shares decreased by 19.13% to $2.41. The market value of their outstanding shares is at $325.9 million.
  • Streamline Health Solns (NASDAQ:STRM) shares fell 18.22% to $2.29. The market value of their outstanding shares is at $9.7 million.
  • OncoCyte (NASDAQ:OCX) shares decreased by 17.98% to $2.51. The market value of their outstanding shares is at $71.7 million.
  • Citius Oncology (NASDAQ:CTOR) shares declined by 17.84% to $0.76. The company's market cap stands at $54.6 million.
  • Sensei Biotherapeutics (NASDAQ:SNSE) stock fell 9.14% to $0.36. The market value of their outstanding shares is at $9.0 million. As per the news, the Q4 earnings report came out 2 days ago. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.